Member Info for inanaco

Moditope RNS announced the SP was 18p remember it well

the adjuvant trial takes years as you have to wait for the return of the cancer

the Keytuda/scib1 trial has Soild tumor as well which can be scanned

its very similar ...

£1 ... up 100% = £2 up 100% = £4 .. up 100% = £8

then you are into fractions ...

if you put a £1 in the calculator x 1000% = £10

but at the end of the day the number of interest is 9 .... that is the profit ...

what Hurdles are left ...........

none

we now know that these hydrophobic peptides can be combined with Amplivant ...

Modi 2 .............. next

Bet the ISA Pharma Board are drinking champagne tonight ...

That's Fantastic ............ buy buy buy I believe that is popular in Lozans posts ........ biggest headache removed !! the most advanced vaccine ever built ..

Jury is out now ... getting bad numbers is not good when you have built a "personal Vaccine" those numbers should have been astonishing .. its probably a £200,000 treatment ... look at the work involved ..

have you not seen this Torq. https://www.fiercebiotech.com/biotech/roche-biontech-post-low-response-rate-cancer-vaccine-trial

https://www.nature.com/articles/d41586-019-03072-8

Bio N tech needs a winner .................... keep an eye open

Roche’s Genentech paid BioNTech $310 million in upfront and near-term milestones in 2016 to gain access to mRNA-based personalized cancer vaccines.

"gain access"

is that the deposits Ruck ..... ?

The companies reason that mRNA vaccines encoding selected neoepitopes can be manufactured for each individual tumor's mutanome signature, resulting in targeted cancer cell death by triggering tumor-specific immune responses.

Genentech agreed to pay BioNTech $310 million in upfront and “near-term” payments tied to achieving unspecified milestones. The companies also agreed to share equally all development costs and any potential profits for certain programs.

The companies’ collaboration agreement gives BioNTech rights to co-promote some products that arise from the agreement in the U.S. and certain countries, including Germany and other major European markets. For other products that Genentech opts not to commercialize, BioNTech said, it may have sole commercialization rights under certain circumstances.

BioNTech agreed to manufacture mRNA cancer vaccines for clinical studies, and Genentech will manufacture for commercial supply. BioNTech said it will have the right to manufacture commercial product as part of the global supply network.

The companies expect to complete their collaboration agreement in the fourth quarter, subject to customary closing conditions that include clearance under the Hart–Scott–Rodino Antitrust Improvements Act.

The collaboration with Roche comes nearly a year after BioNTech inked an up-to-$1.5 billion alliance with Sanofi to discover and develop up to five mRNA cancer immunotherapies—a deal large enough to be included in GEN’s list of Top 15 Immuno-Oncology Collaborations, published earlier this month.

Professor Lindy Durrant, Chief Scientific Officer of Scancell commented:

“We are keen to collaborate on this exciting project to add HAGE to our TRP-2/gp100 vaccine to target GBM. It is an aggressive disease and we believe the high avidity T cells generated by ImmunoBody® will be needed to control its growth.”

Dr Stephanie McArdle, a scientist in the John van Geest Cancer Research Centre at Nottingham Trent University, said:

“Vaccines can be extremely powerful when correctly formulated, so we are very hopeful that combining HAGE and TRP-2/gp100 with Scancell’s ImmunoBody® technology will lead to better disease outcomes.”

Glioblastoma its a hybrid version of SCIB1

No ...

why waste effort ... see the light.

The USA also has lights bermuda ....

bit selective arn't you bermuda .... ....... "it won't see the light of day" ............... answer yes it will ............ orphan status ...

""" RR - let's not forget the SCIB1 Europe patent expires 2028. If its 4-5 years away - then it won't see the light of day."""

try reading the post better next time .

but thank you for pointing out that yes ext. planning should be considered by the BOD

In a letter dated June 18, Rep. Carolyn Maloney (D-NY), chairwoman of the House Committee on Oversight and Reform, Rep. Raja Krishnamoorthi (D-IL), chairman of the committee’s Subcommittee on Economic and Consumer Policy, along with Rep. James Clyburn (D-SC), chairman of the Select Subcommittee on the Coronavirus Crisis, offered suggestions as to how Hahn could improve public confidence in any Covid-19 vaccines his agency might authorize. They also invited the commissioner to brief their staff on the topic on July 2.

Francis Collins NIH
Specifically, the lawmakers advocated for basing any approval on Phase 3 trials with at least 30,000 participants, a threshold the lawmakers expressed confidence in as it was proffered as of sufficient statistical power by Francis Collins, director of the National Institutes of Health, in an interview with CNN. Further, vaccine approval trials should include a demographically varied population, the lawmakers wrote.

To improve transparency, the lawmakers also asked Hahn to commit to including the FDA Vaccine and Related Biological Products Advisory Committee in reviewing any potential vaccine candidates and the National Vaccine Advisory Committee (an agency of the Health and Human Services department) as a resource to help advise on “difficult and sensitive questions of how to prioritize limited quantities of an approved vaccine—who is first in line.”

try this for a thought

These data suggest that SM-88 affects autophagic mechanisms, and follow-up experiments are underway to determine whether the increases in LC3B expression are due to """"autophagy induction""""" or blockade of autophagosome and lysosome fusion.

https://s22.q4cdn.com/265040820/files/doc_downloads/scientific-presentations/2020/AACR2020_Tyme_Poster5998_Final.pdf

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0137675

I will Frame it .... B 26% ..... now what can i do with that ?

nobody builds a road with pea Gravel ... that is for land drainage and pipe work support